Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  • STATUS
    Recruiting
  • End date
    Jun 26, 2022
  • participants needed
    105
  • sponsor
    Groupe Francophone des Myelodysplasies
Updated on 21 July 2021
anemia
hla-a
cell transplantation
cytopenia
lenalidomide
blood transfusion
vidaza

Summary

Comparison of survival in patients with or without a matched donor at 36 months

Description

Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling) received an allogeneic hematopoietic stem cell transplantation.

Patients without a matched donor received the best available treatment. All patients will be followed at least 36 months or until the end of the study.

Details
Condition miller-dieker syndrome, MYELODYSPLASTIC SYNDROME, Myelodysplastic Syndromes (MDS), MDS, myelodysplastic syndromes, myelodysplastic syndrome (mds)
Treatment Transplantation
Clinical Study IdentifierNCT02757989
SponsorGroupe Francophone des Myelodysplasies
Last Modified on21 July 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note